Welcome to our dedicated page for LakeShore Biopharma Co. SEC filings (Ticker: LSBCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is dedicated to the SEC-related disclosure activity of LakeShore Biopharma Co., Ltd (LSBCF), previously known as YS Biopharma. While no individual SEC filings are listed here, the company has stated in its public announcements that it remains a reporting company with the U.S. Securities and Exchange Commission and that it will use SEC filings to communicate key corporate events.
In connection with its transition from The Nasdaq Capital Market to the OTC Pink Open Market, LakeShore Biopharma indicated that it continues to file reports with the SEC. The company also announced that, following a Nasdaq delisting determination based on minimum bid price requirements and prior reverse stock split history, its ordinary shares and warrants began trading on the OTC Pink Open Market under LSBCF and LSBWF. These developments are typically reflected in current reports and other regulatory submissions.
For its going‑private transaction, LakeShore Biopharma has stated that it will furnish a current report on Form 6‑K to the SEC that will include the Agreement and Plan of Merger with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. as an exhibit. The company also plans to prepare and mail a proxy statement to shareholders and to file a Schedule 13E‑3 transaction statement with the SEC, which will include the proxy statement. These documents are intended to provide detailed information about the merger terms, shareholder voting, and the company’s transition to private ownership.
On Stock Titan, users can monitor when such filings are made available through the SEC’s EDGAR system and use AI-powered tools to obtain simplified explanations of complex documents such as Form 6‑K, proxy statements, and Schedule 13E‑3, helping them understand how LakeShore Biopharma describes its corporate actions and governance changes.
LakeShore Biopharma Co., Ltd has called an extraordinary general meeting of shareholders for February 12, 2026 at 11 a.m. (Beijing time) in Beijing. Shareholders will be asked to consider and vote on authorizing and approving a previously announced Agreement and Plan of Merger with Oceanpine Skyline Inc. and its subsidiary Oceanpine Merger Sub Inc., along with a related Cayman Islands plan of merger.
At the effective time of the merger, Merger Sub will merge into LakeShore Biopharma, which will survive as a wholly owned subsidiary of Oceanpine Skyline Inc. If completed, the merger will result in LakeShore Biopharma becoming a privately held company, and its ordinary shares and warrants will no longer be quoted on any public marketplace, including the OTC Pink tier, and will cease to be registered under the U.S. securities laws.
The board of directors, following a unanimous recommendation from a special committee of independent directors, has approved the merger documents and resolved to recommend that shareholders vote FOR the proposals. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 are entitled to attend and vote at the meeting. Additional details are provided in the Schedule 13E-3 transaction statement and definitive proxy statement filed with the SEC.